Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 The effect of combined treatment with anti-IL-9 and anti-IL-5 or their isotype control on cell profiles in differenttissue compartments

From: Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9

  IsC of anti-IL9 + IsC of anti-IL-5 Anti-IL-9 + Anti-IL-5 Anti-IL-5 + IsC of anti-IL-9 Anti-IL-9 + IsC of anti-IL-5
Bone marrow eosinophils(%): 19.3 ± 2.5 3.6 ± 0.6** 3.6 ± 0.7** 18.4 ± 2.2
Immature eos. (%) 13.4 ± 2.1 2.3 ± 0.4** 2.3 ± 0.4** 14.8 ± 2.1
Mature eos. (%) 5.9 ± 0.6 1.2 ± 0.3** 1.4 ± 0.5** 3.7 ± 0.4*
Blood cells (total no., ×106/ml): 1.9 ± 0.2 1.5 ± 0.6 1.3 ± 0.3 1.7 ± 0.2
Neutrophils (×106/ml) 0.7 ± 0.1 0.8 ± 0.3 0.56 ± 0.1 0.7 ± 0.1
Eosinophils (×106/ml) 0.3 ± 0.1 0.1 ± 0.03* 0.1 ± 0.02* 0.3 ± 0.04
Monocytes (×106/ml) 0.3 ± 0.04 0.2 ± 0.04 0.2 ± 0.1 0.2 ± 0.03
Lymphocytes (×106/ml) 0.5 ± 0.1 0.4 ± 0.2 0.5 ± 0.1 0.5 ± 0.1
BAL cells (total no., ×104/ml): 109.3 ± 1.9 44.5 ± 7.6 45.9 ± 3.3 92.4 ± 8.8
Macrophages (×104/ml) 18.9 ± 1.9 11.8 ± 1.0 11.7 ± 0.3 16.9 ± 3.4
Neutrophils (×104/ml) 5.4 ± 1.7 3.8 ± 0.7 4.6 ± 1.0 4.9 ± 1.2
Eosinophils (×104/ml) 67.9 ± 15.1 20.0 ± 6.3* 18.8 ± 2.1* 54.8 ± 6.0
Lymphocytes (×104/ml) 16.8 ± 3.2 8.5 ± 1.8 10.7 ± 1.2 15.5 ± 4.5
  1. Balb/c mice sensitized to OVA were subjected to repeated allergen exposure (OVA; 100 μg i.n. on five consecutive days).
  2. Neutralizing anti-IL-9 (100 μg/animal i.p.) and anti-IL-5 (50 μg/animal i.p.) treatment or their isotype controls treatment, or single antibody in a combination with respective isotype control, were given before the allergen exposure. BAL was performed 24 hours after the last allergen exposure. Data represent mean ± SEM (n = 5 per point). * p < 0.05 and ** p < 0.01 compared with the isotype control antibodies treated group. IsC – isotype control.